Myasthenia gravis MasterClass 2
Halifax Hall, Sheffield University Campus
Endcliffe Vale Road
About myasthenia gravis (MG)
Myasthenia gravis is a rare neuromuscular disorder affecting about 15 in every 100,000 people in the UK. It is a chronic, autoimmune condition that causes muscle weakness and excessive muscle fatigue.
Rationale for education in MG
There is significant variation in both provision for, and access to treatment and support for people with MG across the UK. Meanwhile, whilst the rapidly changing treatment landscape is providing novel treatment opportunities, this may in turn widen those inequalities.
The majority of patients with MG are managed within general neurology. We want to ensure existing general neurologists and registrars, pharmacists, specialist nurses and allied health professionals all understand their role in effectively diagnosing, treating and managing people with MG, can work collaboratively to provide good services, and are confident in when and how to escalate complex patients to specialist services and support.
Through this education, we hope to reduce variance and improve access to treatment and care for people with MG.
Aim of education
This course seeks to:
raise awareness of MG, its characteristics and ideal management in core neurology services
improve mainstream practice through increased knowledge of available treatments and new care pathways
improve timely access to specialist care through increased understanding of complex cases and when to escalate care.
Who is this course for?
The intended audience is:
- general neurologists, including registrars and newly qualified consultants
- specialist nurses
- allied health professionals
General neurologists manage around one third of patients with MG in general clinics and may require updates on the condition and emerging research and practice around diagnosis, management and treatment.
Pharmacists are key to supporting neurology teams with knowledge of and access to relevant treatments for MG, and supporting them with the latest treatment algorithms and pathways will improve patient access to these, in turn.
Specialist nurses and neuromuscular AHPs play a pivotal role in supporting MG patients on a day to day basis and often are their first port of call. Courses such as this will help provide an upskilling opportunity within the UK, relevant to the NHS.
This course is for UK healthcare professionals only.
Cost of the course
The course is fully funded including a travel allowance that will be reimbursed after the MasterClass. There will be a £100 deposit required to secure your place, this will be invoiced to you upon confirmation. This deposit will be refunded within 30 days of completing the MasterClass. → Please note, terms and conditions
Please note that no deposit is required for virtual delegates.
One nights accommodation is included for the night of the MasterClass (20th March) at the venue; Halifax, Hall, Sheffield University Campus, S10 3ER.
If you wish to stay any additional nights the cost is £82.50 per night including breakfast (costs are subject to change). Once you have completed the form, should you require accommodation, you will be contacted about any payment.
Bedrooms will be allocated on a first come first serve basis, starting at the meeting venue, Halifax Hall hotel.
Additional rooms will be allocated at their next door sister hotel, Jonas hotel at £75 per night including breakfast at Halifax Hall hotel (costs are subject to change)
Programme - last updated 18th December 2023
Book your place now
This meeting has been funded by sponsorship from Alexion Pharma UK Ltd, argenx UK Ltd and UCB Pharma Ltd. The sponsors have had no control over the organisation or educational content of this activity.
ChairsDr Channa Hewamadduma
Consultant neurologist and honorary senior lecturer, Sheffield Teaching Hospitals NHS Foundation Trust Prof Saiju Jacob
Consultant neurologist, University Hospitals Birmingham Dr Maria Elena Farrugia
Consultant neurologist, NHS Greater Glasgow and Clyde Prof Maria Isabel Leite
Associate professor and consultant neurologist, University of Oxford
Myasthenia gravis nurse specialist, Queen Elizabeth University Hospital Dr Alan Kirk
Consultant thoracic surgeon, Golden Jubilee National Hospital Dr Jennifer Spillane
consultant neurologist Dr David Gilligan
Consultant Clinical Oncologist Fiona Norwood
Neuromuscular consultant, Kings College London NHS Foundation Trust John McConville
Dr David Gilligan
Consultant clinical oncologist, Cambridge University Hospitals & Royal Papworth Hospitals
Raising awareness, improving outcomes
Neuromuscular Academy is the first bespoke course for healthcare professionals to receive expert training in neuromuscular conditions like spinal muscular atrophy.